PMC7358086_01
H&E staining of tumor sample by biopsy.. Notes: (A) Magnified 40 times; and (B) Magnified 200 times.
OTT-13-6749-g0001.jpg
PMC7358086_01_OTT-13-6749-g0001.jpg
F0001
According to the biopsy findings from the solitary mass on the left chest wall, the patient was diagnosed as lung adenocarcinoma with metastasis on the left chest wall, suggesting metastatic disease (Figure 1).
Timeline of events since the diagnosis and summary of administered treatments.
OTT-13-6749-g0002.jpg
PMC7358086_01_OTT-13-6749-g0002.jpg
F0002
Subsequently, he received combined chemotherapy (pemetrexed, cisplatin, docetaxel) with bevacizumab as second-, and third-line treatment, respectively (Figure 2). Cervical magnetic resonance imaging (MRI) showed the emerging lesion, which was finally confirmed with pathologic findings by biopsy (Figure 2).
Integrative genomics viewer (IGV) screenshots displaying the chimeric reads from targeted sequencing.. Notes: (A) EGFR exon 20 mutation (p.T790M, c.2369C>T, frequency as 4.17%), and EGFR exon 20 mutation (p.C797S, in trans to T790M, c.2390G>C, frequency as 0.37%); (B) CTNNB1 exon 3 alteration (p.S37F, c.110 C>T, frequency as 2.03%).
OTT-13-6749-g0003.jpg
PMC7358086_01_OTT-13-6749-g0003.jpg
F0003
NGS, including 550 tumor-related genes using a plasma sample was conducted to search the potential targets, the results of which suggested EGFR exon 20 mutation (p.T790M, c.2369C>T, frequency as 4.17%), EGFR exon 20 mutation (p.C797S, trans to T790M, c.2390G>C, frequency as 0.37%), and CTNNB1 exon 3 alteration (p.S37F, c.110 C>T, frequency as 2.03%, Figure 3).